中国医保药品价格谈判回顾和展望  

Review and Prospects of Medical Insurance Price Negotiation in China

作　　者：胡善联[1] HU Shanlian(School of Public Health,Fudan University,Shanghai 200000,China)

机构地区：[1]复旦大学公共卫生学院,上海200000

出　　处：《卫生经济研究》2024年第1期9-13,共5页

摘　　要：目的:总结2018—2023年中国医保药品价格谈判的实践经验,对未来的工作提出建议。方法:通过文献回顾、收集官方公布的数据和网络报道资料,对当前医保药品价格谈判的政策和实践进行总结分析。结果:谈判药品平均降价50%~60%,但也存在有待解决的问题。未来医保药品价格谈判工作需要更加关注价值谈判组织体系、标准和方法的建立,重视价值谈判的立法和规制,使价格谈判工作更加公正、公平和透明化。结论:我国的药品价格谈判成绩斐然,充分发挥了政府主导和市场机制的作用,通过价值谈判保障了创新药物的可得性和可及性,在新药需求无限性和医保基金有限性之间找到了平衡点。Objective To sum up the practical experience of medical insurance drug price negotiation between 2018 and 2023 and make some suggestions for future improvements.Methods Through literature review,official data collection and public opinion analysis from website.Results The average rate of price reduction is at the range of 50%-60%.The evaluation conditions,evaluation indexes,evaluation methods,thresholds and unfinished agenda are introduced as well.The author puts forward three suggestions for the future drug price negotiation in China,i,e.,the establishment of the organization system for value negotiation,standards and methods of price negotiation,legislation and regulation of value negotiation in order to make the drug price negotiations more scientific,fairness and transparency.Conclusion China has made remarkable achievements in drug price negotiation,giving full play to the role of government-led and market mechanism,and providing Chinese people with the availability and accessibility of innovative drugs through the present value negotiation.A balance has been reached between the unlimited demand for innovative drugs and the limited availability of health insurance funds.

关 键 词：药品价格谈判 战略购买 价值谈判 药物经济学 评审条件 

分 类 号：R19[医药卫生—卫生事业管理]